Operational Costs Compared: SG&A Analysis of Rhythm Pharmaceuticals, Inc. and Iovance Biotherapeutics, Inc.

A Decade of SG&A Trends in Biotech: Rhythm vs. Iovance

In the ever-evolving biotech industry, operational costs are a critical factor in determining a company's financial health. Over the past decade, Rhythm Pharmaceuticals, Inc. and Iovance Biotherapeutics, Inc. have shown significant shifts in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Iovance's SG&A expenses surged by over 1,000%, reflecting their aggressive expansion and investment in administrative capabilities. Meanwhile, Rhythm Pharmaceuticals experienced an even more dramatic increase, with their SG&A costs skyrocketing by nearly 9,600% during the same period.

Key Insights

• 2014-2018: Both companies maintained relatively modest SG&A expenses, with Iovance consistently outspending Rhythm.
• 2019-2023: A notable shift occurred as Rhythm's expenses caught up and eventually surpassed Iovance by 2023, indicating a strategic pivot towards scaling operations.

These trends highlight the dynamic nature of the biotech sector, where strategic investments in operational infrastructure can significantly impact a company's trajectory.